Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderGlobeNewsWire • 04/10/24
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business UpdateGlobeNewsWire • 04/02/24
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsGlobeNewsWire • 03/02/24
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeGlobeNewsWire • 02/28/24
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20Accesswire • 02/15/24
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark OfficeGlobeNewsWire • 02/13/24
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/23
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine ConferenceGlobeNewsWire • 10/31/23
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to BuyZacks Investment Research • 10/30/23
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader WebinarGlobeNewsWire • 10/25/23
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 10/24/23
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 10/20/23
Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25thAccesswire • 10/19/23
Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug DependenceGlobeNewsWire • 10/19/23
Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership AwardGlobeNewsWire • 10/18/23
Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use DisorderGlobeNewsWire • 09/28/23
Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/05/23
Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on AlcoholismGlobeNewsWire • 08/28/23
Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/21/23